Critical Analysis on the Mechanism of Action (moa) of the Anti-Cd38 Monoclonal Antibody Isatuximab in Multiple Myeloma (Mm)

Monoclonal antibodies (mAbs) targeting CD38 are demonstrating remarkable efficacy, particularly when combined with anti-MM agents. Thus, in-depth understanding of the MoA of anti-CD38 mAbs is of utmost importance to design rational treatment combinations. Notably, while there is considerable data about the MoA of Daratumumab, there is virtually no data about the MoA of Isatuximab.